Senses Disorder TRIZ Cases

Cyclodextrins replace proteoglycans in collagen matrices to form transparent, mechanically strong biomimetic gels.

Gamma-Glu-Cys-Gly peptides activate the calcium receptor while reducing side effects and improving permeability.

Polycyclic compounds inhibit lysophosphatidic acid receptors, resolving the trade-off between therapeutic effectiveness and drug development complexity.

Amniotic cytokine formulations alleviate chronic dry eye symptoms by combining amniotic membrane, fluid, and bioactive agents into a stabilized composition.

Beta-beta-intramolecularly-crosslinked PEGylated hemoglobin conjugates convert nitrite to nitric oxide, reducing vasoconstriction while delivering oxygen.

Pyridazinone compounds inhibit Met kinase to suppress tumor growth while reducing inflammation and toxicity.

Deuterated isotopologues of a quinazoline piperidine compound modify pharmacokinetic properties to control angiogenesis and inhibit cytokine production.

Spirocyclic amide derivatives merge muscarinic antagonism and beta-adrenergic agonism into a single molecular entity.

Atoh1 transcription factor drives stem cell differentiation into hair cells, resolving the inability of endogenous cells to regenerate spontaneously.

Formula I compounds target mGluR2 and mGluR5 receptors to treat schizophrenia and Alzheimer's disease with high specificity.

A non-steroidal compound inhibits inflammatory pathways to treat allergic diseases.

Genetically modified mesenchymal stem cell exosomes improve delivery efficiency while reducing immune system activation.

A bifunctional fusion protein binds VEGF and PDGF ligands to inhibit dual signaling pathways.

Synthetic 2-pyridone derivatives inhibit human neutrophil elastase, preventing uncontrolled tissue destruction in chronic obstructive pulmonary disease.

4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-benzoic acid inhibits platelet aggregation via selective 5-HT2A receptor antagonism.

Increasing lutein concentration to at least 50 mcg/liter raises plasma levels, reducing retinopathy of prematurity risk.

Segmented peptides target specific cytokines to reduce inflammation without harmful side effects.

Novel UDP compounds target the P2Y6 receptor to treat neurodegenerative disorders and pain by reducing plaque burden and improving cognitive function.

Segmented diphtheria toxin R domain inhibits HB-EGF pathway while reducing toxicity and immunogenicity of full-length toxins.

Low affinity antibodies avoid rapid receptor saturation to increase central nervous system uptake and prolong therapeutic exposure.

Small molecule indazolones replace macromolecular antibodies to reduce manufacturing complexity while maintaining potent TNF inhibition.

Substituted imidazo[2,1-b]thiazole compounds modulate the mGluR5 receptor to treat chronic and neuropathic pain without opioid side effects.

Hydrophilic particle coatings sustain therapeutic agent release in eye compartments, reducing inflammation and intraocular pressure.

Anti-Gal3 antibodies alleviate persistent symptoms by addressing underlying inflammatory processes in eye diseases.

Frondoside A restores transport function by removing deposited materials and reversing age-related retinal aging.

Selective prostaglandin EP2 agonist amides modulate aqueous humor outflow, addressing insufficient pressure control in secondary glaucoma cases.

Cleaving fluorogenic substrates via C3 convertase enables early high-risk drusen detection and AMD progression prediction.

Novel carnosine derivatives release nitric oxide to lower intraocular pressure, addressing side effects and limited duration of existing glaucoma treatments.

Copper-infused articles prevent bacterial relapses by releasing ions that penetrate tissue barriers without direct contact.

Chimeric toxin combines C1 binding with C2 translocation to resolve specificity and efficiency trade-offs in neural delivery.

A petrolatum aqueous composition stabilized by multiple nonionic surfactants prevents oil layer separation and precipitation.

A filamentous implant with shape memory material delivers therapeutic agents to the suprachoroidal space.

Porphysomes combine porphyrins with phospholipid bilayers to enable targeted imaging and therapy.

Replacing waxes with pentapeptide-17 and tetrapeptide-12 resolves the contradiction between thickening appearance and smudging damage.

Segmented antibody design selectively targets C3b-dependent pathways to reduce inflammatory mediators without compromising classical host defense functions.

Formula I compound inhibits tau protein kinase 1 activity via specific structural affinity.

ASMase inhibitors reverse autophagic blockage, restoring retinal pigment epithelium integrity and reducing inflammation without invasive injections.

A myelin basic protein peptide composition induces immune tolerance to treat multiple sclerosis.

Replacing aspartic acid with cysteic acid strengthens hydrogen bonds, improving adhesion inhibition effectiveness.

CRISPR/Cas genome editing targets RS1, RL2, and LAT genes to reduce viral replication and provide curative treatment for herpes simplex virus.

Targeting IL-11 trans signaling avoids severe inflammation and cancer risks linked to broad TGFβ1 inhibition.

A PEDF-derived peptide composition uses a vinyl pyrrolidone-vinyl acetate copolymer stabilizer to maintain structural integrity in buffered solutions.

Adsorbing omega-3 polyunsaturated fatty acids and resveratrol onto inert substrates creates stable solid formulations.

Parabacteroides distasonis strains lower cytokine levels and alleviate symptoms in Th17-mediated autoimmune diseases.

Novel pyridine and pyrimidine derivatives act as histone deacetylase inhibitors with optimized pharmacokinetic profiles.